对抗菌药物防突变浓度及突变选择窗两概念的探讨与思索

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (1): 21-24.

对抗菌药物防突变浓度及突变选择窗两概念的探讨与思索

黄瀚^1,2, 刘世坤²

¹湖南省医药学校, 长沙 410000, 湖南;
²中南大学湘雅医学院附三医院药剂科, 长沙 410013, 湖南

收稿日期:2007-09-25 修回日期:2007-10-21 出版日期:2008-01-26 发布日期:2020-10-13
通讯作者: 刘世坤,男, 博士, 教授, 研究方向:临床药理学。Tel:13787088883 E-mail:l8618496@126.com
作者简介:黄瀚, 男, 硕士研究生, 研究方向:临床药理学。Tel:13787260535 E-mail:huanghan5670568@126.com

Discussion and considerations on the mutant prevention concentration and mutant selective window

HUANG Han^1,2, LIU Shi-kun²

¹Hunan Medical College, Changsha 410000, Hunan, China;
²Department of Pharmacy, Third Affiliated Hospital of Xiangya Medical College, Central South University, Changsha 410013, Hunan, China

Received:2007-09-25 Revised:2007-10-21 Online:2008-01-26 Published:2020-10-13

摘要/Abstract

摘要： 防突变浓度(MPC) 及突变选择窗(MSW) 是由Zhao X 等近几年提出的防耐药变异的新概念。结合文献, 本文对MPC 及MSW 几个相关问题进行了探讨, 并简单综述了抗菌药物防耐药变异应用策略。

关键词: 防突变浓度, 突变选择窗, 最低抑菌浓度, 耐药变异

Abstract: The mutant prevention concentration (MPC) and mutant selective window (MSW) were new conceptive theories of resistance mutantion preventation which were raised by Zhao X and Drlica K et al. In this paper, the conceptions of MPC and MSW and some could related issues were discussed. Finally how to prevent resistance mutantion was reviewed.

Key words: mutant prevention concentration, mutant selective window, minimum inhibitory concentration, resistance mutantion

中图分类号:

R969

黄瀚, 刘世坤. 对抗菌药物防突变浓度及突变选择窗两概念的探讨与思索[J]. 中国临床药理学与治疗学, 2008, 13(1): 21-24.

HUANG Han, LIU Shi-kun. Discussion and considerations on the mutant prevention concentration and mutant selective window[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(1): 21-24.

参考文献

[1] Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance[J]. J Chemother, 1997, 9(Suppl 1): 29-37.
[2] Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquilonone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus[J]. Antimicro Agents Chemother, 1999, 43(7): 1756-1758.
[3] Zhao X. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolones studies[J]. Clin Infect Dis, 2001, 33(Suppl 3): S147-156.
[4] Drlica K. A strategy for fighting antibiotic resistance[J]. ASM News, 2001, 67(1): 27-33.
[5] Rowe-Magnus DA, Guerout AM, Mazel D. Bacterial resistance evolution by recruitment of super-integron gene cassettes[J]. MolMicrobiol, 2002;43(6): 1657.
[6] Dong Y, Zhao X, Kreiswirth BN, et al. Mutant prevention concentration as a measure of antibiotic potency:studies with clinical isolates of mycobacterium tuberculosis[J]. Antimicrob Agents hemother, 2000, 44(9): 2581-2584.
[7] Zhao J, Dong Y, Zhao X, et al. Selection of antibiotic resistant bacterial mutants:allelic diversity among fluoroquilonone resistant mutantions[J]. J Infect Dis, 2002, 182(2): 517-525.
[8] Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002, 185(4): 561-565.
[9] 袁斌, 刘贵昌, 徐磊. 铜离子杀菌剂灭活SRB 的研究[J]. 腐蚀与防护, 2005, 25(5): 187-188, 199.
[10] Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator2 associated pneumonia in adults:a randomized trial[J]. JAMA, 2003, 290(19): 2588-2598.
[11] 何礼贤. 呼吸机相关肺炎的研究近况[J]. 临床内科杂志, 2004, 21(3): 658-660.
[12] Bodi M, Ardanuy C, Olona M, et al. Therapy for ventilator associated pneumonia: the Tarragona strategy[J]. Clin Microbiol Infect, 2001, 7(1): 32-33.